Table 4.
Factors Influencing CR Achievement by Logistic Regression Model Analysis
| Parameters | Univariate Logistic Regression | Multivariate Logistic Regression | ||||||
|---|---|---|---|---|---|---|---|---|
| p Value | OR | 95% CI | p Value | OR | 95% CI | |||
| Lower | Higher | Lower | Higher | |||||
| Age >60 years | 0.087 | 0.601 | 0.335 | 1.078 | 0.243 | 0.682 | 0.359 | 1.297 |
| Male | 0.501 | 1.310 | 0.596 | 2.882 | – | – | – | – |
| History of HB | 0.075 | 2.278 | 0.919 | 5.645 | 0.299 | 1.684 | 0.630 | 4.496 |
| History of alcohol use | 0.726 | 1.106 | 0.630 | 1.941 | – | – | – | – |
| History of cirrhosis | 0.129 | 1.586 | 0.874 | 2.879 | – | – | – | – |
| Multifocal disease | 0.116 | 0.630 | 0.354 | 1.120 | – | – | – | – |
| Tumor location: left liver | 0.181 | 1.641 | 0.795 | 3.388 | – | – | – | – |
| Tumor location: right liver | 0.772 | 1.087 | 0.619 | 1.911 | – | – | – | – |
| Tumor location: bilobar | 0.180 | 0.648 | 0.344 | 1.222 | – | – | – | – |
| Largest nodule size ≥5 cm | 0.005 | 0.430 | 0.238 | 0.775 | 0.666 | 0.854 | 0.418 | 1.746 |
| Portal vein invasion | <0.001 | 0.188 | 0.078 | 0.457 | 0.011 | 0.242 | 0.081 | 0.719 |
| Hepatic vein invasion | 0.069 | 0.368 | 0.125 | 1.081 | 0.898 | 1.088 | 0.300 | 3.941 |
| Higher ECOG performance status | 0.081 | 0.657 | 0.410 | 1.052 | 0.816 | 0.937 | 0.543 | 1.617 |
| Higher Child–Pugh stage | 0.134 | 0.536 | 0.237 | 1.210 | – | – | – | – |
| Higher BCLC stage | 0.018 | 0.645 | 0.449 | 0.927 | 0.830 | 0.953 | 0.615 | 1.476 |
| Two or more cycles of DEB-TACE treatment | 0.999 | 1.001 | 0.477 | 2.099 | – | – | – | – |
| Previous cTACE treatment | 0.390 | 1.281 | 0.728 | 2.254 | – | – | – | – |
| Previous surgery | 0.636 | 1.167 | 0.616 | 2.211 | – | – | – | – |
| Previous systematic chemotherapy | 0.329 | 2.070 | 0.481 | 8.913 | – | – | – | – |
| Previous radiofrequency ablation | 0.174 | 0.503 | 0.187 | 1.354 | – | – | – | – |
| Previous targeted therapy | 0.886 | 1.126 | 0.222 | 5.720 | – | – | – | – |
| Combination of ordinary embolization agent | 0.080 | 0.574 | 0.309 | 1.069 | 0.731 | 0.880 | 0.425 | 1.824 |
| WBC abnormal | 0.901 | 0.961 | 0.516 | 1.790 | – | – | – | – |
| RBC abnormal | 0.295 | 0.720 | 0.389 | 1.332 | – | – | – | – |
| ANC abnormal | 0.270 | 0.681 | 0.345 | 1.346 | – | – | – | – |
| Hb abnormal | 0.213 | 0.684 | 0.376 | 1.244 | – | – | – | – |
| PLT abnormal | 0.756 | 1.094 | 0.621 | 1.926 | – | – | – | – |
| ALB abnormal | 0.037 | 0.517 | 0.278 | 0.960 | 0.582 | 0.821 | 0.406 | 1.659 |
| TP abnormal | 0.583 | 1.192 | 0.636 | 2.237 | – | – | – | – |
| TBIL abnormal | 0.575 | 1.190 | 0.647 | 2.191 | – | – | – | – |
| TBA abnormal | 0.955 | 1.017 | 0.569 | 1.817 | – | – | – | – |
| ALT abnormal | 0.843 | 0.933 | 0.467 | 1.863 | – | – | – | – |
| AST abnormal | 0.038 | 0.528 | 0.289 | 0.966 | 0.978 | 1.010 | 0.491 | 2.078 |
| ALP abnormal | 0.446 | 0.794 | 0.438 | 1.437 | – | – | – | – |
| BCr abnormal | 0.424 | 0.684 | 0.270 | 1.735 | – | – | – | – |
| BUN abnormal | 0.050 | 0.295 | 0.087 | 1.002 | 0.101 | 0.346 | 0.098 | 1.229 |
| AFP abnormal | 0.067 | 0.587 | 0.331 | 1.039 | 0.363 | 0.740 | 0.388 | 1.414 |
| CEA abnormal | 0.483 | 0.752 | 0.339 | 1.668 | – | – | – | – |
| CA199 abnormal | 0.724 | 0.887 | 0.455 | 1.728 | – | – | – | – |
Data are presented as p value, OR (odds ratio), and 95% CI (confidence interval). Factors affecting CR achievement were determined by univariate logistic regression analysis, while all factors with a value of p ≤ 0.1 were further detected by multivariate logistic regression analysis. A value of p < 0.05 was considered significant. Child–Pugh stage was scored as 0—A, 1—B, 2—C; BCLC stage was scored as 0—stage 0, 1—stage A, 2—stage B, 3—stage C, 4—stage D. The logistic analysis was performed based on these definitions. HB, hepatitis B.